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A single rapamycin dose protects 
against late-stage experimental cerebral malaria 
via modulation of host immunity, endothelial 
activation and parasite sequestration
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Abstract 
Background: Maladaptive immune responses during cerebral malaria (CM) result in high mortality despite oppor‑
tune anti‑malarial chemotherapy. Rapamycin, an FDA‑approved immunomodulator, protects against experimental 
cerebral malaria (ECM) in mice through effects on the host. However, the potential for reduced adaptive immunity 
with chronic use, combined with an incomplete understanding of mechanisms underlying protection, limit transla‑
tional potential as an adjunctive therapy in CM.
Results: The results presented herein demonstrate that a single dose of rapamycin, provided as late as day 4 or 5 
post‑infection, protected mice from ECM neuropathology and death through modulation of distinct host responses 
to infection. Rapamycin prevented parasite cytoadherence in peripheral organs, including white adipose tissue, via 
reduction of CD36 expression. Rapamycin also altered the splenic immune response by reducing the number of acti‑
vated T cells with migratory phenotype, while increasing local cytotoxic T cell activation. Finally, rapamycin reduced 
brain endothelial ICAM‑1 expression concomitant with reduced brain pathology. Together, these changes potentially 
contributed to increased parasite elimination while reducing CD8 T cell migration to the brain.
Conclusions: Rapamycin exerts pleotropic effects on host immunity, vascular activation and parasite sequestration 
that rescue mice from ECM, and thus support the potential clinical use of rapamycin as an adjunctive therapy in CM.
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Background
Infection with the protozoan parasite Plasmodium fal-
ciparum can rapidly progress into a deadly neurologi-
cal syndrome known as cerebral malaria (CM), resulting 
in high rates of morbidity and mortality particularly in 
children under 5  years of age [1, 2]. Amongst infected 
individuals, the transition from mild malaria symptoms, 
including nausea and fever, to CM symptoms, including 
seizures and coma, is currently impossible to predict. 
Furthermore, no efficient treatment exists once severe 
symptoms arise. Therefore, it is urgent to develop novel 
and effective adjunctive therapies for CM.
The mechanisms leading to CM neuropathology 
remain poorly understood. Multiple cellular and molec-
ular events potentially contribute independently or in 
combination to its aetiology. Some of these include the 
sequestration of infected erythrocytes in several organs 
including the brain; activation of vascular endothelial 
cells with up-regulation of adhesion molecules including 
ICAM-1; uncontrolled pro-inflammatory host responses 
to bioactive parasite products; and the activation, migra-
tion and infiltration of immune cells into inflamed tissues 
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[3]. A better understanding of the contribution of these 
events to CM pathology is crucial to develop novel thera-
pies to prevent the progression of the infection to severe 
disease.
The experimental cerebral malaria (ECM) model, 
consisting of infection of the susceptible mouse 
strain C57BL/6 mice with the  Plasmodium berghei 
ANKA strain, mimics several aspects of the neuropathol-
ogy observed in CM patients. In this model, mice suffer 
from recruitment of antigen-specific cytotoxic CD8+ T 
cells to the brain, which destroys the blood–brain bar-
rier (BBB) in a perforin and granzyme B-dependent man-
ner [4, 5]. In turn, disruption of brain vascular integrity 
results in seizures, paralysis, coma and ultimately death 
[6, 7]. Using the ECM model, several studies have iden-
tified modulators of host targets as potential adjunctive 
therapies. These include inhibition of glutamine metabo-
lism by 6-diazo-5-oxo-l-norleucine (DON) [8], activation 
of the nuclear hormone receptor peroxisome proliferator 
activator gamma (PPAR-ɣ) by rosiglitazone [9], and inhi-
bition of the nutrient/energy sensor mechanistic target 
of rapamycin complex 1 (mTORC1) kinase by rapamycin 
[10, 11].
Rapamycin is particularly interesting due to its known 
safety profiles in humans. Rapamycin (sirolimus/rapa-
mune), a partial allosteric inhibitor of mTORC1 kinase 
activity, is FDA approved for use as an immunosuppres-
sant to prevent organ transplant rejection. In the context 
of ECM, acute prophylactic treatment with rapamycin 
during the first 3  days of infection protects mice from 
ECM neuropathology [10, 11]. This protection occurs 
without affecting peripheral parasite growth, but rather 
via induction of activated T cells in the spleen that 
reduce parasite burden, while preventing pathologic 
migration of activated T cells to the brain [11]. Chronic 
rapamycin treatment beginning on day 1 or day 4 of 
infection also protects from ECM, but with the caveat of 
increasing peripheral parasitaemia and increasing pro-
inflammatory cytokines, all suggestive of host immune 
alteration [10]. Based on these observations, it appears 
that factors inherent to timing and dosage determine 
the relative effect of rapamycin on the host immune 
response to parasite infection. Understanding this effect 
is key to enable clinical translation of rapamycin for CM 
treatment. The purpose of this study was to investigate 
a rapamycin dosing strategy that maximizes protection 
from ECM after the emergence of symptoms, but with-
out compromising adaptive immunity. The results pre-
sented herein demonstrate that a single rapamycin dose, 
provided as late as day 5 of infection, protected mice 
from ECM neuropathology via modulation of parasite 
sequestration in peripheral organs, activation of splenic 
immunity, and prevention of neurovascular activation 
and BBB destruction.
Methods
Mice
Wild-type female C57BL/6J mice 8–10 weeks of age were 
purchased from Jackson Labs (Bar Harbor, ME). Animals 
were housed 4–5 per cage and kept under standard labo-
ratory conditions and allowed free access to water and 
food.
Ethics statement
All animal experiments were performed either with the 
approval of the Animal Research Ethics Committee of 
the Canton Bern, Switzerland and the University of Bern 
Animal Care and Use Committee, or the Harvard Medi-
cal Area Animal Care and Use Committee according to 
the PHS Policy on Humane Care and Use of Laboratory 
Animals by Awardee Institutions and NIH Principles for 
the Utilization and Care of Vertebrate Animals Used in 
Testing, Research and Training.
Food
Mice were fed a purified diet (D124570B, Research Diets, 
New Brunswick, NJ) with 72% calories from carbohy-
drate (sucrose, maltodextrin, corn starch), 18% calories 
from protein (casein) and 10% from fat (soybean oil, lard) 
supplemented with 15  mg of PABA per 100  g of food. 
Powder diets were mixed with 1 L/kg diet of hot water 
containing 2% agar; the cooled mixture was given daily to 
mice either on an ad libitum basis.
Malaria infection
Cryopreserved transgenic P. berghei ANKA parasites 
expressing luciferase/GFP under a constitutive promoter 
[12] were thawed and passaged once in vivo before being 
used to infect experimental mice with 0.5 million para-
sitized RBCs/mouse by tail vein injection. Parasites from 
peripheral blood were stained with SYTO16 and the per-
centage of infected cells was calculated by flow cytometry 
[13]. Individual mouse weights and food intake per cage 
were calculated daily.
Luciferase‑based parasite accumulation/sequestration 
assay
Infected mice were sacrificed on the day 6 after infection 
and perfused with cold PBS intracardially. The organs 
were harvested, weighed and homogenized in an equal 
volume/mg tissue of luciferase activity assay buffer (Inv-
itrogen). Equal volumes were mixed with luciferin sub-
strate and measured in a 96 well luminometer (Biotek 
Synergy 2).
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Brain vascular permeability
On day 6 after infection, mice were injected intravenously 
with 200  μL of PBS-2% Evans blue, sacrificed 1  h later, 
and perfused intracardially with cold PBS. Brains were 
harvested, photographed, weighed and placed in 2  mL 
100% formamide (Merck) for 48 h at 37 °C. Absorbance 
of the formamide supernatant was measured at 620 nm. 
Evans blue concentration was calculated from a standard 
curve and results expressed as microgram of Evans blue/
gram of brain tissue.
Intra‑vital microscopy
Intra-vital and ex  vivo imaging were performed in 
5–6  week-old female C57BL/6 mice infected with P. 
berghei ANKA expressing mCherry under the Hsp70 
promoter, and Firefly luciferase under the ef1a promoter 
[14]. A mixture of anaesthetics comprising 125  mg/
kg ketamine (Ketasol, Graeub) and 12.5  mg/kg xylazine 
(Xylason, Graeub), was prepared and diluted in 1 × PBS 
(1:2:5). Mice were injected intraperitoneally with 100 mL 
per 20 g of body weight, of the mixed anaesthetics. Fol-
lowing anaesthesia, mice were injected intravenously 
with 200 µL of 70 kDa fluorescin isothiocyanate (FITC)-
conjugated dextran (Sigma Aldrich, St. Louis, MO) 
diluted in 1 × PBS, at a final concentration of 10 mg/mL. 
Mice were imaged immediately after FITC-Dextan injec-
tion each day post-infection, in a Leica SP8-STED confo-
cal microscope, using a HC PL APAO CS2 63X 1.4NA oil 
immersion objective. In the LeicaSP8-STED microscope, 
a white laser was used, and wavelengths were defined for 
the spectra corresponding to FITC and mCherry. Experi-
ments were performed in three mice at each day post-
infection. The images were assembled and processed 
using Fiji imaging software.
Isolation and analysis of leukocyte populations
Brains and spleens were harvested at the indicated days 
after infection following perfusion with cold PBS. Spleen 
single-cell suspensions were prepared by homogeniza-
tion through a 70  µm cell strainer (BD Falcon). Brains 
were digested with 50 U/mL of type II and IV collagenase 
(Gibco, Invitrogen) in RPMI, and mononuclear cells iso-
lated on a 33% Percoll density gradient (GE Healthcare). 
After lysing red blood cells and determining the total cell 
concentration, cells were incubated with an FcR blocker 
(Miltenyi Biotech), labelled for the extracellular antigens 
CD3, CD8, CD4 (BD Pharmingen), CD69, LFA-1, CD62L, 
CXCR3, CD25 (all from Biolegend), fixed with 4% para-
formaldehyde (PFA) and stained for the intracellular mark-
ers Granzyme B (Biolegend) and Foxp3 (eBioscience) 
using the Cytofix/Cytoperm kit (BD Biosciences) follow-
ing the manufacturer’s instructions. Single fluorochrome-
labelled cells were used to compensate for spectral overlap. 
Isotype-matched fluorescence minus one controls were 
used to set gate cutoffs. Acquisition was performed using 
a BD Fortessa and data analysed using FlowJo (Tree Star 
Inc.).
Histology
Mice were perfused intracardially with PBS on the indi-
cated day  after infection. For morphometric analy-
ses, brains  were fixed in 4% paraformaldehyde in PBS, 
embedded in paraffin, cut and H&E stained using stand-
ard procedures. For immunofluorescence microscopy, 
brains were flash frozen in liquid nitrogen and stored at 
−  80  °C until use. Sections were cut with a cryotome, 
fixed in ice-cold 4% PFA, permeabilized in 0.25% Triton 
X-100, washed in PBS and blocked in 10% normal goat 
serum diluted in TBS-T (TBS buffer containing 0.2% 
Tween 20). After blocking, sections were incubated with 
primary rabbit anti CD31 and rat anti-ICAM-1 (both 
from Abcam, Cambridge, MA) overnight at 4  °C. After 
washing with PBS, sections were labelled with Alexa 488 
goat and rabbit IgG and Alexa 568 goat anti rat IgG for 
2 h at room temperature. After extensive washing, slides 
were mounted in anti-fade mounting media with DAPI 
(Vector Labs, Burlingame, CA). Images were taken with 
a Zeiss Axio observed fluorescence microscope with 
an APOTOME attachment with a 20  ×/0.8 M27 plan-
apochromat objective and an AxioCam monochromatic 
MRm digital camera. Slices stained only with secondary 
antibodies were used to set parameters. For quantita-
tion, all images in both groups were taken using the same 
acquisition parameter. Image processing analysis was 
performed using the using the AxioVision 4.7.1 software 
as well as Fiji imaging software.
Quantitative real‑time PCR
Total RNA was extracted from frozen tissue with RNA 
Bee (Qiagen). Hexamer-primed complementary DNA 
(cDNA) was synthesized with Verso cDNA kit (Thermo 
Scientific) according to manufacturer’s instructions. 
Quantitative real-time PCR was performed with a MyIQ 
(Bio-Rad) using SYBR Green. Relative expression was cal-
culated with the ΔΔCt method. cDNA expression of each 
sample was standardized to RPLA13. Each sample was 
tested in duplicate at least twice. Primer sequences used: 
CCL-5, fwd: 5′-GCAAGTGCTCCAATCTTGCA-3′; rev: 
5′-CTTCTCTGGGTTGGCACACA-3′. CXCL-9, fwd: 
5′-GCCATGAAGTCCGCTGTTCT-3′; rev: 5′-GGGTTC 
CTCGAACTCCACACT-3′. CXCL-10, fwd: 5′-GACGG 
TCCGCTGCAACTG-3′; rev: 5′-GCTTCCCTATGGCC 
CTCATT-3′. ICAM-1, fwd: 5′-GCCTCCGGACTTTCGA 
TCTT-3′; rev: 5′-GTCAGGGGTGTCGAGCTTTG-3′. 
Pb18S, fwd: 5′-AAGCATTAAATAAAGCGAATACATC 
CTTAC-3′; rev: 5′-GGAGATTGGTTTTGACGTTTATG 
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TG-3′. P-Selectin, fwd: 5′ CCCTGGCAACAGCCTTC 
AG-3′; rev: 5′-GGGTCCTCAAAATCGTCATCC-3′. 
VCAM, fwr: 5′-AGTTGGGGATTCGGTTGTTCT-3′; 
rev: 5′-CCCCTCATTCCTTACCACCC-3′.
Immunoblots
Snap frozen tissues were homogenized in 1  mL of lysis 
buffer consisting of 10% glycerol, 1% NP-40, 1  mM 
 MgCl2, 150  mM NaCl, 50  mM β-glycerophosphate, 
20 mM Tris–HCl pH 7.4 supplemented with a protease 
inhibitor and phosphatase inhibitor cocktails (Thermo 
Fisher Scientific, Rockford, IL) with an IKA T10 Ultra-
Turrax (Wilmington, NC) tissue disperser. Homogenized 
samples were centrifuged for 20 min at 10,000g, and the 
protein concentration determined from extracts using 
the Pierce BCA protein assay kit (Thermo Scientific). 
40  μg of protein extract was resolved by SDS-PAGE, 
transferred to Immobilon-P polyvinylidene difluoride 
(PDVF) membranes (Millipore), blocked in 5% skim 
milk diluted in TBST (10 mM Tris–HCl pH 7.4 plus 0.1% 
Tween 20), washed in TBST, and incubated overnight 
at 4  °C with primary antibody (CD36 and tubulin, both 
from Abcam, Cambridge MA) 1:1000 diluted in anti-
body buffer (5% BSA, 0.1% sodium azide in TBST). After 
washing in TBST, membranes were incubated 90 min at 
room temperature with goat anti-mouse or goat anti-
rabbit IgG conjugated with horseradish peroxidase 
(Dako, Carpinteria, CA) diluted 1:5000 in 5% skim milk. 
After extensive washing with TBST, blots were devel-
oped using the Super Signal West Femto chemilumines-
cent substrate kit (Pierce, Thermo Scientific).
In vivo rapamycin treatments
A stock solution of rapamycin (LC Laboratories, Woburn 
MA) dissolved in 100% ethanol was further diluted in 5% 
Tween/5% PEG-400 vehicle solution and was adminis-
tered i.p. to infected mice at 5 or 25 mg/kg/day on day 4, 
5 or 6 of infection; vehicle solution was used as a control.
Statistics
Data are expressed as mean ± SEM unless indicated oth-
erwise. Statistical analyses were performed in GraphPad 
Fig. 1 A single dose of rapamycin rescues mice from late‑stage ECM. a Body weights and food intake of female C57BL6 mice infected with Plas-
modium berghei ANKA on day 0 and injected with vehicle or rapamycin (5 or 25 mg/kg) on day 4 (arrow) post‑infection as indicated. b Circulating 
cytokines over the course of infection in female C57BL6 mice infected with P. berghei ANKA on day 0 (n = 4/time point). c Time course of infection‑
induced brain vasculature permeability. C57BL6 mice (3 per day) were infected with P. berghei ANKA that expresses mCherry (Pb‑mCherry). On the 
indicated day, mice were injected with FITC‑Dextran to analyze intravascular diffusion and extracellular permeability using intra‑vital microscopy. 
Upper panels are composite images showing FITC‑mCherry expression. The lower panels are representative images of the FITC channel, displayed 
as heat‑map LUTs for quantitation. Evaluation of intravascular and extravascular—diffused‑FITC‑dextran mean fluorescence intensity (MFI) is quanti‑
fied and plotted at right. d Survival and peripheral parasitaemia in female C57BL6 mice infected on day 0 and injected with vehicle or rapamycin (5 
or 25 mg/kg) on day 4 (arrow) post‑infection as indicated (n = 5/group). e Survival (n = 9/group) and peripheral parasitaemia (n = 4/group) of mice 
infected on day 0 and treated on day 5 or 6 post‑infection with vehicle alone or with rapamycin (25 mg/kg) as indicated. Values are mean ± SEM
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Prism with Mann–Whitney, one-way analysis of variance 
(ANOVA) or Kaplan–Meier survival tests as indicated.
Results
A single dose of rapamycin rescues mice from late‑stage 
ECM
Previous studies have demonstrated that early rapamy-
cin treatment on days 1–3 post-infection with P. berghei 
ANKA, before onset of symptoms, protects mice against 
ECM pathology and mortality [11]. Here, the efficacy of a 
single injection of vehicle or rapamycin at different doses 
(5 or 25 mg/kg), provided on day 4 post-infection when 
symptoms including weight loss and reduced food intake 
indicative of sickness behaviour emerge (Fig.  1a), was 
tested. At this time point, an increase in circulating pro-
inflammatory cytokines likely causative of this anorectic 
response, including IFN-γ IL-6 and TNFα, was observed 
(Fig.  1b). Also on day 4, increased brain vascular leak-
age was  observed by intra-vital confocal microscopy, 
evidence of initial blood brain barrier dysfunction (BBB) 
(Fig.  1c). Vascular leakage remained elevated on days 5 
and 6 post infection (Fig. 1c).
Clinically, both the high and low doses of rapamycin 
resulted in complete abrogation of neurological symp-
toms, and protected against the high mortality associated 
with this model (Fig.  1d). Although chronic mTORC1 
inhibition can interfere with host immune clearance of 
parasites [10] or inhibit parasite growth directly [15], a 
single rapamycin dose did neither, as peripheral parasi-
taemia levels, compared to vehicle treated controls, were 
not significantly affected (Fig.  1d). Interestingly, infec-
tion-induced anorexia was transiently but significantly 
abrogated on the day after rapamycin treatment, but only 
at the highest dose (Fig.  1b). The efficacy of treatment 
with rapamycin at a later time point (days 5 and 6), when 
brain vascular dysfunction is more pronounced and bet-
ter established, was next tested. As shown in (Fig.  1e), 
mice treated with a single high dose (25 mg/kg) of rapa-
mycin as late as day 5 post infection were also protected 
from neuropathology and death. However, treatment at 
day 6 only conferred a non-significant 25% survival rate 
(Fig. 1e). Nonetheless, neither day 5 nor day 6 rapamycin 
treatment affected the course of peripheral parasitaemia 
(Fig.  1e). Taken together, the results show that a single 
dose of rapamycin, provided as late as day 5 of infection, 
after the emergence of sickness behaviour and vascular 
leakage, protected mice from ECM. In order to establish 
the mechanism(s) involved in the protection afforded 
by rapamycin, subsequent experiments were performed 
using a dosing strategy consisting of one injection of 
5 mg/kg on day 4 post-infection, which maximizes pro-
tection from ECM after sickness behavior and vascular 
leakage associated with ECM have emerged.
Rapamycin inhibits parasite sequestration in peripheral 
organs
Cytoadherence, or sequestration of parasitized red blood 
cells (RBSs) to endothelial cells in peripheral organs 
including white adipose tissue (WAT) and lungs con-
stitutes a mechanism by which mature Plasmodium 
parasites avoid circulation through and clearance by 
the spleen [4]. To monitor sequestration, a P. berghei 
ANKA strain constitutively expressing a GFP-lucif-
erase transgene was employed [12], and used to meas-
ure luminescence in extracts of perfused tissues on day 
6 post-infection. The results demonstrated that a single 
rapamycin treatment on day 4 post infection significantly 
reduced sequestration in lung (Fig. 2a) and WAT, includ-
ing  both perigonadal and subcutaneous depots, relative 
to vehicle-treated controls (Fig. 2b).
The potential mechanisms by which rapamycin reduced 
peripheral sequestration were next explored. In mice and 
humans, the fatty acid receptor CD36 is a major host 
determinant of sequestration in peripheral tissues includ-
ing lung and WAT (but not brain) [16–19]. Interestingly, 
rapamycin treatment resulted in reduced CD36 protein 
expression in WAT but not lungs on day 6 post-infection 
(Fig. 2c, d). These results suggest the existence of CD36 
dependent and independent mechanisms of peripheral 
Fig. 2 Rapamycin treatment inhibits parasite sequestration. C57BL6 
mice were infected with transgenic luciferase‑expressing P. berghei 
ANKA on day 0, and treated with 5 mg/kg of rapamycin (R) or vehicle 
(V) on day 4 post infection. Luciferase activity was measured in per‑
fused tissues at day 6. a Ex vivo luciferase activity indicative of parasite 
sequestration in lung (a) and white adipose tissue (b); perigonadal, 
PgWAT; subcutaneous, ScWAT). c, d Immunoblot and quantifica‑
tion of CD36 protein expression in PgWAT (c) and lung (d) of day 6 
infected mice treated on day 4 with vehicle or rapamycin (5 mg/kg). 
Data are mean ± SEM; n = 5/group
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parasite sequestration, selectively and differentially regu-
lated in different tissues by mTORC1 activity.
Rapamycin inhibits T cell migration capacity and effector 
functions in the spleen
Because sequestration of mature parasites in lungs 
and WAT represents a strategy to avoid clearance of 
parasitized erythrocytes in spleen, reduced sequestra-
tion (Fig. 2) without a significant increase in circulating 
parasitized RBCs (Fig.  1) could potentially  be explained 
by increased splenic clearance. Parasite-derived lucif-
erase activity detected in the spleens from mice treated 
with rapamycin on day 4, tended to be reduced by day 
6 compared to vehicle-treated controls per mg of tissue, 
although this difference did not reach statistical signifi-
cance (Fig.  3a). However, as splenic clearance may also 
destroy parasite luciferase activity, it is not a reliable 
measure of clearance activity.
Host immune cell-based measures of splenic activity 
were next explored. Treatment with rapamycin on day 4 
translated into an increase in total splenocytes, as well as 
an increase in total lymphocytes, including both CD4+ 
and CD8+ T cells, by day 6 post-infection (Fig.  3a). 
Amongst CD8+ T cells, the proportion displaying the 
activated phenotype, characterized by CD69, LFA-1 and 
CXCR3 expression, was significantly reduced following 
rapamycin treatment (Fig.  3b). However, amongst the 
population of activated CD8+, CD69+, LFA1+ T  cells, 
the proportion expressing granzyme was increased 
upon rapamycin treatment, consistent with more robust 
effector function, possibly leading to enhanced clear-
ance (Fig.  3c). Lastly, the proportion of naïve CD62L+ 
CD8+ T cells, characterized of reduced migratory capac-
ity, significantly increased following rapamycin treat-
ment (Fig. 3d). Together, these data suggest that a single 
dose of rapamycin on day 4 of infection alters splenic T 
Fig. 3 Rapamycin alters splenic lymphocyte migratory capacity and effector functions. a Ex vivo luciferase activity in spleen on day 6 after infection 
of mice with transgenic luciferase‑expressing P. berghei ANKA treated with vehicle or rapamycin (5 mg/kg) on day 4. Total numbers of splenocytes, 
spleen lymphocytes and relative numbers of CD4+ and CD8+ T cells of vehicle (V) or rapamycin treated (R) mice on day 6 post infection. b Relative 
CD8+ lymphocyte numbers, with representative dot plots of activated CD8+ T cell populations expressing the indicated markers in the spleen of 
the indicated treatment groups on day 6 post infection. c Relative numbers with representative dot plots of granzyme B+ effector T cells gated 
from the CD3+ CD69+ LFA‑1+ population. d Relative numbers of CD62L+ naïve CD8+ T cells gated from CD3+ splenocytes with representative 
dot plots from the indicated treatment group on day 6 post infection. Data are mean ± SEM; n = 5/group
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cell differentiation, resulting in an overall decrease in T 
cell activation and migratory capacity, but an increase in 
effector function.
Rapamycin modulates the recruitment of effector T cells 
to the brain
The simultaneous presence of parasites and activated 
CD8+ T cells in brains of infected mice is required for 
BBB disruption and ECM neuropathology [4]. Therefore, 
the effect of day 4 rapamycin treatment on T cell accu-
mulation in brains of infected mice by day 6 post-infec-
tion was investigated. Quantitation of leukocytes isolated 
from brains of infected animals after perfusion on day 6 
revealed significantly fewer total leukocytes present in 
the rapamycin group (Fig.  4a), including reduced accu-
mulation of CD4+ and CD8+ T cells (Fig. 4b). Moreover, 
these fewer CD4+ and CD8+ T cells displayed reduced 
expression of activation markers such as CD69 and LFA1 
(Fig.  4c, d), consistent with data in spleen showing that 
mTORC1 inhibition of T cells on day 4 prevented T cell 
activation and trafficking to the brain later in infection.
Modulation of brain vascular endothelial activation 
upon rapamycin treatment
Vascular endothelial cell activation and dysfunction 
is another feature of CM that correlates with pathol-
ogy [20]. mTORC1 plays a key role in controlling the 
expression of endothelial cell adhesion molecules such 
as ICAM-1, VCAM-1 and P-selectin [21–23]. Analysis 
of ICAM-1 expression in brain sections on day 6 post-
infection revealed rapamycin-dependent reduction in 
the intensity of endothelial ICAM-1 expression (Fig. 5a) 
as well as the total endothelial area expressing this adhe-
sion molecule (CD31/ICAM-1 vascular co-localization, 
Fig.  5b). Interestingly, except for VCAM-1, rapamycin 
did not reduce mRNA expression of ICAM-1 or other 
chemokines crucial for T cells migration into the brain 
(Fig. 5c). These results are consistent with effects of rapa-
mycin on neurovascular activation on the post-transcrip-
tional level.
Rapamycin reduces brain pathology
ECM neuropathology results from accumulation of 
infected RBCs in the brain, together with activated 
CD8+ T cells, which promotes destruction of the BBB 
[4, 24]. Having demonstrated vascular leakage starting as 
early as day 4 post-infection, the effect of a single dose 
of rapamycin at this time point on brain pathology  was 
evaluated. Rapamycin treatment on day 4 significantly 
reduced the accumulation of parasites in brains on day 6 
post-infection (Fig. 6a). This result was obtained by quan-
titating luminescence from parasites and confirmed by 
measurement of the parasite-specific Pb18s gene from 
brains using real-time PCR (Fig. 6a).
Fig. 4 Rapamycin modulates the recruitment of effector T cells to the brain. a Total number of leukocytes (in thousands, K) isolated from brains of 
mice treated with vehicle or rapamycin (5 mg/kg) on day 4 and collected on day 6 expressed per brain. b Total numbers with representative dot 
plots of CD4+ and CD8+ T cells from brains as determined by flow cytometry. CD4+ and CD8+ populations where gated from CD3 + cells; n = 5/
group. c, d Total numbers with representative dot plots of activated CD4+ (c) and CD8+ (d) T cells from mice of the indicated treatment group on 
day 6 post infection. Data are mean ± SEM; n = 5/group
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Reduce parasite brain sequestration correlated with 
preserved BBB integrity, as evidenced by reduced vas-
cular leakage of injected Evan’s blue dye in rapamycin-
treated mice (Fig. 6b). Furthermore, histological analyses 
revealed significantly fewer brain haemorrhages in the 
rapamycin-treated group compared to controls (Fig. 6c). 
However, no differences in the size of the haemorrhages 
were observed (Fig. 6c).
Discussion
This study demonstrates for the first time that mTORC1 
inhibition with rapamycin can offer significant protec-
tion against ECM neuropathology even with a single 
dose as late as day 5 post-infection. Consistent with the 
pleiotropic function of its target, mTORC1, protection 
by rapamycin treatment was afforded through inhibi-
tion of multiple pathogenic mechanisms. These included: 
parasite accumulation in peripheral organs in part via 
decreased CD36 expression; splenic CD4+ and CD8+ T 
cell activation and trafficking to the brain; and activation 
of neurovascular endothelium and BBB breakdown. A 
schematic model of the pleiotropic effects of rapamycin 
during infection that result in protection against ECM is 
provided in Fig. 7.
mTORC1 plays a central role in activation and traf-
ficking of antigen-stimulated CD4+ and CD8+ T cells. 
mTORC1 activation prevents homing of naïve and mem-
ory T cells to secondary lymph nodes and instead redi-
rects them to sites of inflammation [25]. This occurs 
through differential regulation of the transcription fac-
tors KLF2 and T-bet [26]. Repression of KLF2 expres-
sion by mTORC1 reduces expression of its targets 
CCR7, CD62L and sphingosine-1 phosphate receptor 1 
(S1PR1) on naïve and memory T cells [26]. At the same 
time, activation of T-bet by mTORC1 increases expres-
sion of CXCR3 and P-selectin ligands that coordinate the 
migration of T cells towards sites of inflammation. T-bet 
dependent gene expression also promotes the expression 
of CD8+ effector molecules in T cells [27, 28]. Interest-
ingly, S1P signaling and T-bet expression have both been 
implicated in the pathology of human and experimental 
CM [29, 30]. In this context, clinical studies have shown 
increased predisposition to CM development in patients 
bearing low SP1, while increased bioavailability via phar-
macological means improves survival and vascular integ-
rity in the ECM model [29]. Furthermore, T-bet ablation 
is associated with protection from ECM [30].
The results presented in this study strongly suggest 
that inhibition of mTORC1 activity in T cells upon rapa-
mycin treatment decreases numbers of splenic effec-
tor T cells having the capacity to migrate into the brain 
(CD8+ CXCR3+) by day 6 of infection, a crucial step in 
ECM pathology [31–33]. Although the total number of 
activated CD69+ CD8+ T cells in the spleen was lower 
in the rapamycin treated group, the percentage of gran-
zyme  B+ effector T cells within this population was 
significantly increased, suggesting increased effector 
capacity. Finally, more CD62L+ naïve T cells were being 
directed to and retained in the spleen after rapamycin 
treatment. Together, this complex pattern of immune 
changes could contribute to increased clearance of para-
sitized RBCs in the spleen while at the same time reduc-
ing migration to the brain. Rapamycin also facilitates the 
generation of memory T cells in several models of infec-
tion and anti-tumor immune response [34, 35]. Future 
studies are required to determine if immunomodulation 
with rapamycin could have benefits on the memory T cell 
Fig. 5 Rapamycin modulaes endothelial activation in the brain. a 
Representative immunohistochemical images of day 6 brains from 
vehicle or rapamycin treated mice, stained for the endothelial marker 
CD31 (green) and ICAM‑1 (red). Bar graph next to the micrographs 
shows the quantitation of the ICAM‑1 mean fluorescence intensity 
(MFI) of over 20 fields of view, each one consisting of multiple optical 
sections 30 μm deep. Scale bar = 50 μm. b Dot plots showing the 
distribution and surface area representing CD31/ICAM‑1 co‑locali‑
zation in endothelial cells by microscopy. Color intensity scale repre‑
sents the frequency of events within the distribution. Bar graph next 
to plots show the quantitation of the surface area presenting ICAM‑1 
co‑localization on CD31 brain endothelial cells. c Relative gene 
expression of chemokines and endothelial activation markers on day 
6 of infection in brains of mice (n = 5/group) treated with vehicle (V) 
or rapamycin (R, 5 mg/kg) on day 4. Gene expression was analyzed 
using the ∆∆CT equation, and fold change is expressed respect to the 
vehicle treated group. Data represent mean ± SEM
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response in addition to affording acute protection against 
deleterious inflammation.
Vascular endothelial cell activation and dysfunction is 
another feature of severe disease upon malaria infection 
[20]. In  vitro, mTORC1 inhibition decreases expression 
of adhesion molecules such as ICAM-1 and VCAM-1 
at the surface of endothelial cells [22, 23]. In the context 
of ECM, a reduction of brain ICAM-1 protein expres-
sion  was observed in the vasculature upon rapamycin 
treatment that could contribute to the reduction of par-
asite and leukocyte sequestration in this organ late in 
infection. However, as neurovascular activation in ECM 
is influenced by cytotoxic T cell migration to the brain, 
the relative cause and effect attributable to reduced 
adhesion molecule expression vs. immunomodulation 
will be difficult to disentangle using systemic rapamycin 
treatment.
While sequestration of parasitized RBCs in peripheral 
organs including WAT occurs both in human and rodent 
CM, the contribution of this process to neuropathol-
ogy is unclear. It is expected that the failure to seques-
ter will facilitate clearance of mature parasitized RBCs 
in the spleen, thus reducing parasite loads. In line with 
this, rapamycin treatment induced a significant decrease 
in parasite sequestration in both WAT and lungs without 
affecting circulating parasite levels, consistent with an 
increase in clearance by the spleen. Mechanistically, the 
data presented suggests both direct and indirect roles of 
mTORC1 in promoting sequestration. In specific tissues, 
this could be due to modulation of CD36 expression. 
Reduction of CD36 expression in WAT upon rapamycin 
treatment suggests a direct effect of mTORC1 in control-
ling cytoadherence via CD36 in this tissue. Conversely, 
CD36 was not differentially regulated in lungs. How-
ever, the fact that rapamycin significantly  reduced para-
site sequestration in lungs of infected mice suggests the 
existence of alternative mechanisms in addition to CD36 
required to modulate parasite cytoadherence in this 
Fig. 6 Rapamycin reduces brain pathology. a Luciferase activity and Pb18S expression indicative of luciferase‑transgenic parasite accumulation in 
the brain of perfused mice (n = 5/group) on day 6 of infection treated on day 4 with vehicle (V) or rapamycin (R, 5 mg/kg) as indicated. b Quantita‑
tion of Evan’s blue dye in brains and photographs of representative brains from mice (n = 4–5/group) treated with vehicle or rapamycin (5 mg/kg) 
on day 4 and injected with Evan’s blue dye on day 6 after infection to assess blood–brain barrier function. c Representative micrographs of brains 
from vehicle and rapamycin treated (5 mg/kg) mice 6 days after malaria infection. Upper panels show representative images of the thalamic area, 
which presents disperse micro and macro‑haemorrhages (arrows) scattered throughout the parenchyma. It is also evident in this image the vascu‑
lar leukostasis (Inset), caused by clustering of leukocytes and infected RBCs (arrow head) within the blood vessels. Mid panels show representative 
images of the hypothalamus region presenting leukostasis and scattered micro‑haemorrhages (arrows), defined as haemorrhagic areas smaller than 
2 μm2 (Inset). Lower panels show representative images comparing the cerebellum of vehicle and rapamycin treated mice. Inset shows a macro‑
haemorrhage in the molecular layer. Macro‑haemorrhages (arrows) were defined as haemorrhages exceeding 2 μm2. Quantitation of total number 
of brain haemorrhages per field of view are shown. Morphometric analysis showing the surface area of haemorrhages in whole brain sections are 
also shown. Hemorrhages were divided in micro‑haemorrhages (< 2 μm2) and macro‑haemorrhages (> 2 μm2). Data represent the mean ± SEM of 
over 100 fields of view. Scale bar = 100 μm. Inlets are ×40 magnified images of the selected regions
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organ. Additional studies are required  to elucidate such 
CD36-independent mechanisms of lung cytoadherence 
regulated by rapamycin.
The robust protection obtained upon a single dose of 
rapamycin late in infection justifies the evaluation of 
rapamycin analogs with improved pharmacological prop-
erties as potential therapeutic agents against ECM immu-
nopathology. Torins, for instance, have effects against 
Plasmodium parasites; however, their effect as immu-
nomodulators during ECM has not been assessed [15]. 
Interestingly, dihydroartemisinin, the active metabolite 
of all artemisinin-derived anti-malarials, has also been 
reported to inhibit mTORC1 in cells [36] and mice [37]. 
However, the time course of reduced mTORC1 activ-
ity is strongly suggestive of indirect effects mechanisti-
cally distinct from rapamycin. In addition, rapamycin has 
also been reported to have microbicidal activities against 
Plasmodium parasites [38]. However, the in  vitro rapa-
mycin concentrations necessary to affect parasite growth 
are much higher, suggesting this is not the mechanism 
underlying protection against ECM in most experimental 
settings [38].
Clinical testing and development of adjunctive thera-
pies remain an urgent need due to the ongoing high 
fatality rates and long-term deleterious consequences of 
CM. In this context, novel potential adjunctive therapies 
with the ability to afford protection against ECM late in 
infection have been recently described. These include 
rosiglitazone and the glutamine analog 6-diazo-5-oxo-
l-norleucine (DON) [8–10, 39]. Rosiglitazone, a direct 
PPAR-ɣ agonist, is effective in preventing death from 
ECM when given together with artesunate at days 5/6 
post-infection [9, 39]. Rosiglitazone increases survival 
and phagocytosis of infected erythrocytes via upregula-
tion of CD36 expression on macrophages [9, 39], and has 
proven safe in patients with uncomplicated P. falciparum 
malaria, thus prompting its use as an  adjuvant therapy 
against CM [9, 40, 41].
DON, on the other hand, protects mice via inhibi-
tion of T cell degranulation, despite having no effect on 
accumulation of these cells in the brain when treatment 
was  started on day 5 and continued every other day or 
every day. The pharmacokinetics and safety profiles of 
DON in humans will be crucial factors in establishing 
the appropriateness of the drug for the treatment of CM. 
In this context, a potential advantage of rapamycin is the 
ability to give a single effective dose, thus mitigating the 
potential side effects of continuous treatment.
Conclusion
The data presented here demonstrate that rapamycin, a 
FDA-approved mTORC1 inhibitor, offers significant pro-
tection against ECM symptoms and mortality in mice 
even after a single dose administered late in infection via 
inhibition of multiple pathogenic mechanisms, and place 
rapamycin as a strong candidate for clinical use as an 
adjunctive therapy against human CM.
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